Difference between revisions of "Pentraxin 2 (PRM-151)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "http://www.cancer.gov" to "https://www.cancer.gov") |
||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism per [ | + | Class/mechanism per [https://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=755555 NCI Drug Dictionary]: A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, recombinant human serum amyloid P/pentraxin 2 (PRM-151) may inhibit myofibroblast generation by preventing the differentiation of circulating monocytes into fibrocytes and profibrotic macrophages. PTX2 is a circulating plasma protein that belongs to the class of pattern recognition receptors (PRR) of the innate immune system. |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Line 13: | Line 13: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
+ | [[Category:Recombinant medications]] | ||
[[Category:Myelofibrosis medications (investigational)]] | [[Category:Myelofibrosis medications (investigational)]] |
Latest revision as of 20:21, 27 June 2024
General information
Class/mechanism per NCI Drug Dictionary: A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, recombinant human serum amyloid P/pentraxin 2 (PRM-151) may inhibit myofibroblast generation by preventing the differentiation of circulating monocytes into fibrocytes and profibrotic macrophages. PTX2 is a circulating plasma protein that belongs to the class of pattern recognition receptors (PRR) of the innate immune system.
Route: IV
Extravasation: n/a
Preliminary data
Myelofibrosis
Also known as
- Code name: PRM-151